Literature DB >> 31648511

[Clofazimine suspension formulation for treating extremely resistant tuberculosis in a nursing patient].

M Arrieta Loitegui1, C García Muñoz, M González Sevilla, C Rosas Espinoza, J M Ferrari Piquero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31648511      PMCID： PMC6913083     

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN： 0214-3429            Impact factor:   1.553


× No keyword cloud information.
  4 in total

1.  Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.

Authors:  Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling
Journal:  Clin Infect Dis       Date:  2014-10-30       Impact factor: 9.079

2.  [Diagnosis of tuberculosis in pediatrics. Consensus document of the Spanish Society of Pediatric Infectology (SEIP) and the Spanish Society of Pediatric Pneumology (SENP)].

Authors:  D Moreno-Pérez; A Andrés Martín; N Altet Gómez; F Baquero-Artigao; A Escribano Montaner; D Gómez-Pastrana Durán; R González Montero; M J Mellado Peña; C Rodrigo-Gonzalo-de-Liria; M J Ruiz Serrano
Journal:  An Pediatr (Barc)       Date:  2010-03-23       Impact factor: 1.500

3.  [Tuberculosis treatment for children: An update].

Authors:  María José Mellado Peña; Begoña Santiago García; Fernando Baquero-Artigao; David Moreno Pérez; Roi Piñeiro Pérez; Ana Méndez Echevarría; José Tomás Ramos Amador; David Gómez-Pastrana Durán; Antoni Noguera Julian
Journal:  An Pediatr (Engl Ed)       Date:  2017-07-18

Review 4.  Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  K Dheda; K C Chang; L Guglielmetti; J Furin; H S Schaaf; D Chesov; A Esmail; C Lange
Journal:  Clin Microbiol Infect       Date:  2016-10-15       Impact factor: 8.067
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.